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Objectives. The hypothesis of this study was that metabolites of
trichloroethylene (TCE), dichloroethylene (DCE) and related
compounds were responsible for fetal cardiac teratogenic effects
seen when TCE or DCE is consumed by pregnant rats during
organogenesis. Identification of teratogenic metabolites would
allow more accurate assessment of environmental contaminants
and public health risks from contaminated water or possibly
municipal water supplies which, when chlorinated, may produce
these potentially dangerous chemicals.
Background. Human epidemiologic studies and previous tera-
togenic studies using chick embryos and fetal rats have shown an
increased incidence of congenital cardiac lesions in animals
exposed to TCE and DCE.
Methods. Metabolites and compounds studied in drinking
water exposure included: trichloroacetic acid (TCAA), monochlo-
roacetic acid (MCAA), trichloroethanol (TCEth), carboxy meth-
ylcystine (CMC), trichloroacetaldehyde (TCAld), dichloroacetal-
dehyde (DCAld), and dichlorovinyl cystine (DCVC). Compounds
were administered to pregnant rats during fetal heart develop-
ment.
Results. Fetuses of rats receiving 2,730 ppm TCAA in drinking
water were the only group that demonstrated a significant in-
crease in cardiac defects (10.53%) compared with controls (2.15%)
on a per fetus basis (p 5 0.0001, Fischer’s exact test), and a per
litter basis (p 5 0.0004, Wilcoxon and p 5 0.0015, exact permu-
tation tests). Trichloroacetic acid also demonstrated an increased
number of implantation and resorption sites (p < 0.05) over
controls. Other maternal and fetal variables showed no statisti-
cally significant differences between treated and untreated groups.
Conclusions. Of the metabolites tested, only TCAA appeared to
be a specific cardiac teratogen in the fetus when imbibed by the
maternal rat.
(J Am Coll Cardiol 1998;32:540–5)
©1998 by the American College of Cardiology
Halogenated hydrocarbons, such as trichloroethylene (TCE),
and its metabolic products, are among the most common water
supply contaminants in the United States and around the world
(1). Also, in the presence of natural organic material, chlori-
nation of municipal water to eliminate coliform bacteria has
been shown to produce a number of quantitatively important
chlorinated organic compounds, including the TCE metabo-
lites chloral hydrate (TCAld), trichloroacetic acid (TCAA) and
dichloroacetic acid (DCAA) (2–4). The United States popu-
lation consumes chlorinated drinking water, which is a major
source of ingestion of these chlorinated organic compounds
(5). Thus, both contaminated water and municipal water are
both potential sources of exposure to TCE and its metabolites.
An epidemiologic study in the Southwestern United States
found an association between the presence of TCE in contam-
inated water and an increased incidence of major cardiac
malformations in children born to mothers residing in contam-
inated areas (6). Although this case-controlled study demon-
strated an association between the halogenated hydrocarbon
contaminants and congenital heart defects, it was not designed
to establish a cause and effect relation. As a result, in vivo
studies were undertaken to determine the possible teratoge-
nicity of TCE and dichloroethylene (DCE) in both avian and
rat models.
Avian studies (7,8) demonstrated that TCE and DCE had
both general and cardiac teratogenic effects on the developing
chick. Subsequent controlled studies in the pregnant rat model
(9,10) determined an increased frequency of cardiac teratoge-
nicity in fetuses after direct intrauterine exposure to TCE and
DCE. Compounds were then administered to the dam in
drinking water during the critical days of fetal organogenesis to
more closely simulate human exposure conditions. Similar
increases in cardiac teratogenesis were observed. Other re-
searchers demonstrated an increased frequency of specific
congenital cardiac malformations following treatment with
chlorinated hydrocarbons in other rodent models (11–19). A
recent study of whole embryo exposure to TCE and other
related compounds (including metabolites), demonstrated em-
bryotoxicity and various developmental abnormalities (20).
Our purpose was to determine whether the parent com-
pounds (TCE or DCE), or one or more of their metabolites
was linked with the presence of cardiac defects. Compounds
tested in this study included TCAA, monochloroacetic acid
(MCAA), trichloroethanol (TCEth), carboxy methylcystine
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(CMC), TCAld, dichloroacetaldehyde (DCAld) and dichlo-
rovinyl cystine (DCVC). Based on work by others, the most
suspect metabolites were weak acids such as TCAA or MCAA
or an alcohol such as TCEth (4,11–20). A nonchlorinated
hydrocarbon was included to determine if the chlorine atom
played a role in teratogenicity.
Methods
This study was conducted in Association for Assessment
and Accreditation of Laboratory Animal Care accredited and
Institutional Animal Care and Use Committee governed facil-
ities at the University of Arizona Animal Care Center. Animals
were quarantined for 7 days before study. Study groups
consisted of virus free, young, sexually mature Hsd:Sprague
Dawley SD rats (Harlan Sprague Dawley, Inc., Indianapolis,
Indiana). Females, 225 6 30 g, were housed in pens of four,
and the males, 300 6 50 g, were housed individually. All rats
had access to water and Teklad 4% Mouse Rat diet (Teklad,
Madison, Wisconsin) ad libitum. Each animal was identified by
an ear notch code. The number of animals in each group was
determined by a power calculation to detect a threefold
increase in the malformations over controls.
Daily vaginal smears or impedance measurements (Estrous
Impedance Monitor, Fine Scientific Instruments, Inc., Phoe-
nix, Arizona) were obtained from all females to determine
stages of the estrous cycle. When in proestrus, female rats were
placed in a cage with one male overnight. The presence of a
vaginal plug and/or spermatozoa in the vaginal smear the
following morning was considered indicative of day 1 of
pregnancy. Each rat was carefully observed throughout preg-
nancy and weight gain was monitored and recorded daily.
Administration of agents. Control animals for this study
received distilled water throughout pregnancy. On day 1 of
pregnancy, and continuing throughout pregnancy, their regular
drinking water was replaced with treated water. Compounds
tested included TCAA, MCAA, TCEth, CMC, TCAld, DCAld
and DCVC. Solutions of the various compounds were pre-
pared by dilution with distilled water and, if necessary, titrated
with NaOH to a pH of approximately 7.0, a pH similar to that
of the control water. Each water bottle was placed in a specially
made metal casing to reduce light exposure and subsequent
chemical breakdown. The amount of water consumed by each
pen of animals (4 maximum) was monitored and recorded
every 24 h. Bottles were cleaned and fresh solutions prepared
daily.
Levels of metabolites were based on the dosage equivalent
to that expected if all of the high dose of TCE (1,100 ppm, the
limit of solubility, and the maximal TCE dose tested) was to
breakdown completely into that given metabolite. The level of
TCAA was similar to the dose tested by other investigators for
comparison purposes (11). To achieve uniformity between the
tri- and monochloroacetic acids, MCAA was also given at an
equivalent dose. Dichloroacetic acid was not tested because
this had already been performed by other investigators (12).
Examination of fetuses. For all groups, on day 22 of
gestation, approximately 1 day before parturition, each preg-
nant rat was weighed before euthanasia in a carbon dioxide
chamber. An examination was then conducted for any abnor-
malities (external and internal) and the gravid uterus and
ovaries removed. The uterus was opened, exposing all fetuses,
implantation sites (sites where the embryo implanted in the
uterus, but did not mature beyond implantation, leaving only a
metrial gland) and resorption sites (sites where fetal develop-
ment began, but stopped at some point during gestation with
only decaying fetal tissue remaining). The position of each site
was recorded. Fetuses and placentas were examined in situ,
then removed and individually examined externally for any
morphologic abnormalities. All fetal placements, weights, pla-
cental weights, crown rump (C/R) lengths and any gross fetal
abnormalities were evaluated by an experienced veterinarian.
Using an Optivisor (Donegan Optical Co., Inc., St. Lenexa,
Kansas) for magnification, the thoracic and abdominal cavities
were opened. All abdominal organs were inspected for any
congenital abnormalities. Exposing the thoracic cavity allowed
observation of the great arterial and venous connections to the
heart in situ. Pulmonary and vena caval attachments were then
incised, as distal to the heart as possible, and the heart
removed. A 27-gauge needle was placed apically in the left
ventricle and the heart gently flushed with 2% gluteraldehyde
solution. Each heart was then placed in an individual vial that
was labeled with a seven digit code (for future “blind” assess-
ment) and placed in the same solution for 24-h fixation. The
heart was then transferred to a 0.1 mol/L phosphate buffer
solution for storage.
Examination of hearts. Individual hearts were dissected
and evaluated using a Nikon SMZ-2T light microscope with an
attached TV camera and monitor (Nikon, Chandler, Arizona).
This allowed excellent visualization and manipulation. Initially,
the heart was examined for any gross morphologic abnormal-
ities from both dorsal and ventral aspects. The heart was then
examined in a step by step protocol which is detailed by
Dawson et al. (10). This method allows visualization of the
atrial septum, aortic and pulmonary vessels, semi-lunar and
atrioventricular valves and the ventricular septum. All con-
firmed abnormalities were agreed upon by the three investiga-
tors: a veterinarian, a pathologist and a pediatric cardiologist.
All abnormal specimens were then photographed using a
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DCAA 5 dichloroacetic acid
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Nikon N2020 camera mounted on the light microscope. De-
coding of the hearts, with respect to treatment, occurred only
after final examination of all hearts and fetuses.
Statistical analysis. For an effect size of a threefold in-
crease over background heart defects, a power analysis of 90%,
with an alpha error of 0.05 and a beta error of 0.1, determined
that a sample size of 100 was needed for statistical significance.
Statistics for the individual fetal data were analyzed by using
Fisher’s exact test. The Wilcoxon and exact permutation tests
were used to determine the significance of the litter outcome
(21).
Results
Data compiled for treatment groups of all compounds
included: 1) maternal parameters; 2) in situ uterine abnormal-
ities observed at necropsy on day 22; 3) fetal parameters; 4)
types of cardiac anomalies, and 5) percent congenital fetal
cardiac anomalies calculated both on a per fetus basis and a
per litter basis. Table 1 contains concentration and dosing
information.
Maternal observations. All maternal rats (138 total) were
healthy throughout the study and without evidence of toxicity.
Steady weight gain occurred throughout pregnancy in all
groups. Ovaries had normal morphologic features. All 138
pregnancies except for two, in which total resorption occurred,
progressed uneventfully. Observations, shown in Table 2,
included weight gain, pregnancy complications and uterine
examination. Weight gain during pregnancy was not signifi-
cantly different for any group of dams. There were no preg-
nancy complications, and all uterine morphologic examina-
tions were normal.
Implantation sites, resorption sites and fetuses. The
uterus was examined for implantation sites, resorption sites,
and live and dead fetuses. External inspection of live fetuses
(n 5 932) and dead fetuses (n 5 9), excluding one fetus that
was too autolyzed to examine, demonstrated no gross morpho-
logic congenital abnormalities in any group. No differences
were found between treated groups and controls for the mean
number of implantation sites and resorption sites using Fish-
er’s exact analysis, except for the TCAA group in which a
significant increase occurred (1.1 average implantation sites
per litter [p 5 0.0006] for TCAA exposure compared with 0.20
average implantation sites per litter for Controls, and 2.7
average resorption sites, per litter [p 5 0.0001] TCAA com-
pared with 0.70 average resorption sites, per litter for controls,
[Table 2]).
Fetuses were analyzed by determining: 1) numbers of live or
dead fetuses (Table 2); 2) fetal weight; 3) placental weight; 4)
C/R length, and 5) external morphology. No significant differ-
ence was found when comparing treated and control fetal
groups for these observations. There were no gross external or
noncardiac internal congenital abnormalities found in any
treated or control groups.
Cardiac anomalies. Several different cardiac malforma-
tions were found and no one lesion or grouping predominated.
Variations of normal morphology similar to those found in
humans were not classified as defects (for example, tricuspid
valve leaflet contribution to complete coverage of a membra-
nous ventricular defect). General types of cardiac defects were
grouped in categories and listed by treatment in Table 3.
Defects were as follows: secundum type atrial septal defects
(n 5 16); hypoplasia of the aorta or pulmonary artery (n 5 9);
aortic valve defects with fused leaflets (bicuspid or tricuspid)
creating aortic valvular stenosis (n 5 2); pulmonary valve
stenosis (n 5 6), including hypoplastic annulus and leaflet
adhesions; hypoplastic mitral valve annulus (n 5 6); tricuspid
valve defects (n 5 1); abnormal looping (n 5 2); atrioventric-
ular septal defect (n 5 1), and both perimembranous (n 5 10)
and muscular (n 5 8) ventricular septal defects. When these
defects were divided into left and right heart abnormalities, the
breakdown demonstrated was of near equal proportion: 11
left-sided versus 13 right-sided defects. Septation defects ap-
peared to be more represented than a difference between
lesions of the left and right sides of the heart.
Quantitative analysis of cardiac abnormalities. A total of
605 control fetal hearts and 941 treated fetal hearts (divided
into seven groups) were examined (Fig. 1). When examining
the fetuses on an individual basis the assumption was made
that each fetus had an equal chance of developing a heart
malformation independent of its litter mates. Because this may
not be the correct assumption, fetal hearts were also evaluated
Table 1. Average Amount of Drinking Water Consumed per Maternal Rat
Water Treatment Normal TCAA MCAA TCEth TCAld DCAld CMC DCVC
Concentration in ppm Water 2,730 1,570 1,249 1,232 174 473 50
Equivalent dosage to ppm (mg/ml) N/A 2.73 1.57 1.249 1.232 0.174 0.473 0.05
Dosage (mg/kg/d) N/A 291 193 153 151 21 58 6
Average amount of “drinking water” consumed
on a daily basis per maternal rat (ml)
46 38 21 53 42 55 55 40
Number of days consuming “drinking water” 21 20* 20* 21 21 21 21 21
Average dose per rat per day (mg/rat/d) N/A 103 33 67 51 10 26 2
Average total consumed during pregnancy by
the rat (mg/rat)
N/A 2,092 612 1,396 1,070 200 546 41
*Exposure was consistent, but due to occasional mechanical failure, days were missed in some rats, thus bringing the average days of consuming treated water in
some groups to ,21 days.
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on a per litter basis to determine the significance of any
increase in number of cardiac abnormalities. The range of
cardiac abnormalities per group ranged from 2.97% to 10.53%
with a control group value of 2.15%. The group imbibing
2,730 ppm TCAA (291 mg/kg/day) during pregnancy had
10.53% abnormal hearts from a total of 114 fetuses. Malfor-
mation rate for the TCAA group was significantly greater than
control rats on a per fetal basis (p 5 0.0001, Fisher’s exact test)
and a per litter basis (Wilcoxon and exact permutation tests
(p 5 0.0004, and a p 5 0.0015 respectively). No other group
demonstrated a significant increase in cardiac malformations
compared with controls.
Discussion
Prior studies by the same investigators demonstrated an
increased incidence of cardiac defects when the parent com-
pounds TCE and DCE were administered in a similar rat
model (10). The current study demonstrated that exposure to
a major metabolite, TCAA administered in drinking water,
resulted in increased numbers of implantation and resorption
sites, and selective cardiac teratogenicity.
The logic for our initial dose selection was based on the
level of the metabolite that would be expected to be produced
from the breakdown of the maximum TCE dose tested
(1,100 ppm) (9). Smith et al. (11) administered a gavage dose
of 330 mg/kg/day TCAA, which was similar to the drinking
water dose given in this study (291 mg/kg/day). In the Smith et
al. study, a dose dependent increase in implantation sites and
resorption sites and an increase in frequency of soft tissue
malformations (mainly cardiovascular) occurred at levels of
330 mg/kg/day and above.
The types of cardiac defects found in this study (Table 3)
are consistent with those in our previous studies (7–10). A
variety of defects was found with no particular lesion, group-
ing, or syndrome predominating.
The defects observed in this study are different from those
reported by Smith, et al. (11). In the Long-Evans rat they
reported mainly malaligned ventricular septal defects. How-
ever, their method of examining fetuses was by section micros-
copy, which is quite different from the dissection method used
in this study. Our method is more sensitive for lesions, such as
adhered valve cusps, separating oval fossa defects from true
secundum atrial defects and detection of abnormal valve
dimensions.
A nonchlorinated metabolite of TCE, CMC, was included
to determine if the presence or absence of the chlorine atom is
involved in the production of cardiac defects. Carboxy meth-
ylcystine and all the metabolites we tested, except the TCAA,
produced no cardiac abnormalities. It is of interest to note that
at a high dose, MCAA produced no effect, whereas TCAA did
produce cardiac defects, and increased numbers of implanta-
tion and resorption sites. Smith et al. (17) studied the effects of
DCAA, and found cardiac teratogenic effects at high levels of
exposure.
Although it is accepted that “no animal test and battery ofTa
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tests will provide complete assurance in the prediction of
human teratologic risk” (22), the similarities in the timing and
sequencing of events during crucial periods of embryogenesis
and organogenesis (particularly cardiogenesis) between hu-
mans and rats suggest that the rat is a suitable nonprimate
choice for studying teratogenic effects on developing fetuses
(22–25). Other advantages of the rat model include: the
availability of genetically uniform strains, well documented
reproductive cycles, gestational stages, multiparity, high fertil-
ity rates and resistance to surgical manipulation (26–32). The
Sprague-Dawley rat model was specifically selected because of
the very low incidence of spontaneous cardiovascular anoma-
lies (25) and the general similarity to the human incidence and
types of spontaneous cardiac abnormalities that occurred
(22–24). All these factors contribute to the potential impor-
tance of these findings and their possible application to the
human situation.
Study limitations. 1) It was not within the scope of this
research to determine the mechanisms responsible for these
defects, but rather, we studied the incidence and types of
cardiac defects that occur. 2) Certain cardiac and great vessel
abnormalities may have gone undetected, such as coarctation
of the aorta, regurgitant valves and abnormal coronary artery
distribution beyond the ostium. 3) As in previous studies, it was
not possible to substantiate delivery of compounds to the fetal
tissue due to sensitivity limitations of our gas chromatography
methods. Failure to demonstrate cardiac defects associated
with other metabolites in this study may be due to their lack of
teratogenesis or their inability to cross the fetal membranes
and/or the rapid clearance of those compounds in the maternal
body. 4) This study sought a causative agent and did not address
a dose response. 5) Doses in this study were higher than those
typically found in contaminated wells and water supplies.
The low number of cardiac defects found in non-TCAA
groups does not preclude the cardiac teratogenicity of these
metabolites, but rather demonstrates that an increase could
not be detected at the power level we employed. Also, these
findings do not prove that human cardiac defects are caused by
TCAA. However, this study raised awareness of the potential
cardiac teratogenicity of some halogenated compounds.
Figure 1. Percent of abnormal hearts (fetal basis).
CMC 5 carboxy methylcystine; DCAA 5 dichloroacetic
acid; DCAld 5 dichloroacetaldehyde; DCVC 5 dichlo-
rovinyl cystine; MCAA 5 monochloroacetic acid;
TCAA 5 trichloroacetic acid; TCAld 5 trichloroacetal-
dehyde; TCEth 5 trichloroethanol. *Statistical signifi-
cance between the treated group and the control group.
Table 3. Types of Heart Malformations
Group Normal TCAA MCAA TCEth TCAld DCAld CMC DCVC
Heart abnormalities Water 2,730 ppm 1,570 ppm 1,249 ppm 1,232 ppm 174 ppm 473 ppm 50 ppm
Abnormal looping 2
AO hypoplasia 1 1 1 1
PA hypoplasia 2 1 2
Atrial septal defects 7 3 3 2 1
Mitral valve defects (hypoplasia or
ectasia)
1 1 1 2 1
Tricuspid valve defects (hypoplasia
or ectasia)
1
Ventricular septal defects:
Perimembranous (subaortic) 2 4 3 1
Muscular 2 1 1 2 2
Atrioventricular septal defects 1
Pulmonary valve defects 1 3 1 1
Aortic valve defects 1 1
AO 5 Aorta; Abn 5 abnormal; PA 5 pulmonary artery.
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Conclusions. These data demonstrate that specific fetal
cardiac teratogenicity occurs when TCAA is administered in
drinking water to a maternal rat, in the doses studied. TCAA
also results in an increased number of implantation sites and
resorption sites when compared with the control animals.
These data therefore support the hypothesis that not only the
parent compound, but also a metabolic breakdown product of
TCE may cause selective cardiac teratogenesis in a mammalian
model.
Although the experimental studies discussed here cannot be
extrapolated directly to humans, many processes of cell divi-
sion, migration and differentiation are common to all mam-
mals during gestation. It is anticipated that further investiga-
tion might elucidate the mechanisms relating exposure to
certain halogenated hydrocarbons and cardiac defects.
The authors would like to thank Haiyan Cui, PhD, Biostatistics Department,
University of Arizona, for performing the statistics for this study.
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